Literature DB >> 2279633

Discrimination of liver cirrhosis from chronic hepatitis by analysis of serum cholinesterase isozymes using affinity electrophoresis with concanavalin A or wheat germ agglutinin.

T Hada1, T Ohue, H Imanishi, H Nakaoka, A Hirosaki, S Shimomura, M Fujikura, Y Matsuda, T Yamamoto, Y Amuro.   

Abstract

Isozymic alteration of serum cholinesterase (ChE) was investigated in patients with chronic liver diseases using affinity electrophoresis with concanavalin A (Con A) or wheat germ agglutinin (WGA). On Con A-containing agarose gel electrophoresis, three bands with enzyme activity (named bands I to III, from the anodic side to the cathodic) were observed in sera of normal controls. Disappearance of band II was observed in 50% (15/30) of cirrhotic patients, but only one of 20 patients with chronic hepatitis lacked band II of the serum ChE isozymes. Meanwhile, WGA-containing agarose gel electrophoresis revealed that normal controls had four ChE isozymes (named bands I to IV from the anodic side to the cathodic). These four isozymes were also observed in patients with chronic hepatitis. However approximately 67% (20/30) of cirrhotic patients lacked band II of ChE isozymes. When these two affinity electrophoreses were used in combination, 22 (73%) of 30 cirrhotic patients had isozymic alteration of their serum ChE on either Con A-containing or WGA-containing agarose gel electrophoresis, or both. Thus, affinity electrophoreses with Con A and WGA seemed to be useful methods in differentiating liver cirrhosis from chronic hepatitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2279633     DOI: 10.1007/bf02779185

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  12 in total

1.  Novel cholinesterase expression in the HuH-7 cell line.

Authors:  T Hada; T Yamamoto; H Imanishi; S Takahashi; Y Amuro; K Higashino; J Sato
Journal:  Tumour Biol       Date:  1987

Review 2.  Structure of human serum cholinesterase.

Authors:  O Lockridge
Journal:  Bioessays       Date:  1988-10       Impact factor: 4.345

3.  Brain cDNA clone for human cholinesterase.

Authors:  C McTiernan; S Adkins; A Chatonnet; T A Vaughan; C F Bartels; M Kott; T L Rosenberry; B N La Du; O Lockridge
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

4.  Alteration of serum cholinesterase isozyme in patients with liver cirrhosis.

Authors:  T Hada; T Ohue; H Imanishi; H Nakaoka; A Hirosaki; M Fujikura; Y Amuro; K Higashino
Journal:  Clin Chim Acta       Date:  1988-11       Impact factor: 3.786

5.  Atypical serum cholinesterase eliminated by orthotopic liver transplantation.

Authors:  G F Khoury; J Brill; L Walts; R W Busuttil
Journal:  Anesthesiology       Date:  1987-08       Impact factor: 7.892

6.  Location of disulfide bonds within the sequence of human serum cholinesterase.

Authors:  O Lockridge; S Adkins; B N La Du
Journal:  J Biol Chem       Date:  1987-09-25       Impact factor: 5.157

7.  [Isolation and physico-chemical characterization of cholinesterase in human serum].

Authors:  H Haupt; K Heide; O Zwisler; H G Schwick
Journal:  Blut       Date:  1966-11

8.  Intrinsic hepatic clearance and Child-Turcotte classification for assessment of liver function in cirrhosis.

Authors:  J C Barbare; R E Poupon; P Jaillon; S Prod'homme; F Darnis; R Y Poupon
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

9.  Evaluation of the degree of desialylation of serum C1-inactivator and haemopexin.

Authors:  N S Serbource-Goguel Seta; M C Bordas; J M Féger; J A Davy; G M Durand
Journal:  Clin Chim Acta       Date:  1984-11-30       Impact factor: 3.786

10.  N-acetylglucosaminyltransferase III in human serum, and liver and hepatoma tissues: increased activity in liver cirrhosis and hepatoma patients.

Authors:  K Ishibashi; A Nishikawa; N Hayashi; A Kasahara; N Sato; S Fujii; T Kamada; N Taniguchi
Journal:  Clin Chim Acta       Date:  1989-12-15       Impact factor: 3.786

View more
  1 in total

1.  Increased plasma alpha (1 --> 3)-L-fucosyltransferase activities in patients with hepatocellular carcinoma.

Authors:  T Hada; K Fukui; M Ohno; S Akamatsu; S Yazawa; K Enomoto; K Yamaguchi; Y Matsuda; Y Amuro; N Yamanaka
Journal:  Glycoconj J       Date:  1995-10       Impact factor: 2.916

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.